Literature DB >> 9794371

Chemotactic activity of soluble Fas ligand against phagocytes.

K Seino1, K Iwabuchi, N Kayagaki, R Miyata, I Nagaoka, A Matsuzawa, K Fukao, H Yagita, K Okumura.   

Abstract

A recombinant soluble form of human Fas ligand (sFasL) was tested for its chemotactic activity against human and mouse polymorphonuclear neutrophils (PMN) by the Boyden chamber method. sFasL exhibited a potent chemotactic activity against both human and mouse PMN and HL-60 cells when differentiated into neutrophils or monocytes. A neutralizing anti-FasL mAb abolished the chemotactic activity, while control mAb did not. Ligation of Fas by either IgM- or IgG-type anti-Fas mAb also induced PMN migration. PMN derived from lpr mice that express few Fas molecules did not respond to sFasL. In contrast, those derived from lpr(cg) mice that express Fas molecules with a mutated death domain normally responded to sFasL chemotaxis. These results directly indicated a chemotactic activity of sFasL against PMN and suggest a novel signaling function of Fas, which appears to be independent of the death domain-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794371

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.

Authors:  N P Restifo
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

2.  Apoptosis in rat spontaneous chronic pancreatis: role of the Fas and Fas ligand system.

Authors:  S B Su; Y Motoo; M J Xie; N Sawabu
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

3.  Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice.

Authors:  Esma S Yolcu; Hong Zhao; Laura Bandura-Morgan; Chantale Lacelle; Kyle B Woodward; Nadir Askenasy; Haval Shirwan
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

4.  Pancreatic islets engineered with a FasL protein induce systemic tolerance at the induction phase that evolves into long-term graft-localized immune privilege.

Authors:  Kyle B Woodward; Hong Zhao; Pradeep Shrestha; Lalit Batra; Min Tan; Orlando Grimany-Nuno; Laura Bandura-Morgan; Nadir Askenasy; Haval Shirwan; Esma S Yolcu
Journal:  Am J Transplant       Date:  2020-01-05       Impact factor: 8.086

5.  Proinflammatory consequences of transgenic fas ligand expression in the heart.

Authors:  D P Nelson; E Setser; D G Hall; S M Schwartz; T Hewitt; R Klevitsky; H Osinska; D Bellgrau; R C Duke; J Robbins
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  The regulation of FasL expression during activation-induced cell death (AICD).

Authors:  T Nguyen; J Russell
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

7.  Age-dependent changes in FasL (CD95L) modulate macrophage function in a model of age-related macular degeneration.

Authors:  Hui Zhao; Jayeeta Roychoudhury; Teresa A Doggett; Rajendra S Apte; Thomas A Ferguson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-07       Impact factor: 4.799

8.  Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation.

Authors:  G Matute-Bello; R K Winn; M Jonas; E Y Chi; T R Martin; W C Liles
Journal:  Am J Pathol       Date:  2001-01       Impact factor: 4.307

9.  Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3 analogue.

Authors:  Mark A Wortinger; Joseph W Foley; Patrick Larocque; Derrick R Witcher; Michael Lahn; Joseph A Jakubowski; Andrew Glasebrook; Ho Yeong Song
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  Dynamic changes of IL-2/IL-10, sFas and expression of Fas in intestinal mucosa in rats with acute necrotizing pancreatitis.

Authors:  Sheng-Chun Dang; Jian-Xin Zhang; Jian-Guo Qu; Zheng-Fa Mao; Xu-Qing Wang; Bei Zhu
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.